Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia
Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the..
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the..
Generated 1Q 2024 net FUROSCIX^® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the..
The world’s first personalised mRNA cancer jab for melanoma – which also has the potential to stop lung, bladder and kidney..